Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Open-label, Parallel Group Extension Part to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Potential Efficacy of Multiple Doses of ONO-2808 in Patients With Multiple System Atrophy

NCT05923866 is registered in ClinicalTrials.gov with Ono Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05923866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05923866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Open-label, Parallel Group Extension Part to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Potential Efficacy of Multiple Doses of ONO-2808 in Patients With Multiple System Atrophy
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 22, 2023
Completion date
October 31, 2027
Enrollment
92 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

multiple system atrophy (msa)